A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-naïve participants with locally advanced or metastatic squamous non-small cell lung cancer.

Timeline

Start: 2016-11
Primary completion: 2017-12
Completion: 2019-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Necitumumab	Monoclonal antibody	—	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Gemcitabine	Small molecule	—	Intravenous

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Summary

Timeline

Drugs

Indications